MARKET

STRO

STRO

Sutro Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.07
+0.13
+1.09%
Closed 16:00 10/20 EDT
OPEN
11.53
PREV CLOSE
11.94
HIGH
12.25
LOW
11.53
VOLUME
90.31K
TURNOVER
--
52 WEEK HIGH
13.91
52 WEEK LOW
6.00
MARKET CAP
433.06M
P/E (TTM)
-10.8965
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Dipping Their Toes Into Sutro Biopharma, Inc. (STRO)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]
Insider Monkey · 10/12 17:10
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company today announced that it has been recognized as Best New Drug Developer at the World ADC Digital Awards, held during the World ADC Digital Event.
PR Newswire · 09/21 12:00
Why Sutro Biopharma's Stock Is Trading Higher Today
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Monday after peer company Immunomedics, who also works to treat cancer,
Benzinga · 09/14 14:22
Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers
Gainers:  Agenus (AGEN) +13%, Achieve Life Sciences (ACHV) +7%, Agile Therapeutics (AGRX) +7%, Akouos (AKUS) +7%, Adial Pharmaceuticals (ADIL) +6%.Losers: Satsuma Pharmaceuticals (STSA) -75%, Precipio (PRPO) -22%, Sutro Biopharma (STRO) -18%, Athenex (ATNX) -16%, Spero Therapeutics (SPRO) -15%.
Seekingalpha · 09/10 15:10
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off.
Benzinga · 09/06 17:25
Sutro Biopharma, Inc. (NASDAQ:STRO) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Simply Wall St. · 09/04 12:27
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of STRO. Analyze the recent business situations of Sutro Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average STRO stock price target is 19.83 with a high estimate of 23.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 25.09M
% Owned: 69.94%
Shares Outstanding: 35.88M
TypeInstitutionsShares
Increased
34
6.32M
New
25
6.84M
Decreased
12
643.61K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Director
Connie Matsui
Chief Executive Officer/Director
William Newell
Chief Financial Officer
Edward Albini
Chief Human Resource Officer
Linda Fitzpatrick
Chief Scientific Officer
Trevor Hallam
Vice President
Andreas Maderna
Vice President - Finance/Controller
Regina Cheng
Vice President - Operations
Carlos Lugo
Vice President
Kristin Bedard
Vice President
Craig Berman
Vice President - Business Development
Brunilda Shtylla
Other
Shabbir Anik
Other
Arturo Molina
Director
James Panek
Director
Daniel Petree
Independent Director
Michael Dybbs
Independent Director
John Freund
Independent Director
Joseph Lobacki
Independent Director
Shalini Sharp
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About STRO
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sutro Biopharma Inc stock information, including NASDAQ:STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.